Disease · MONDO_0016718

choroid plexus carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. choroid plexus carcinoma. Diseases, record MONDO_0016718. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016718

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: choroid plexus carcinoma; Open Targets
Open Targets ID: MONDO_0016718; Open Targets
Other names: anaplastic choroid plexus papilloma, carcinoma of choroid plexus, carcinoma of the choroid plexus, carcinoma, choroid plexus, malignant, choroid plexus carcinoma (morphologic abnormality); Open Targets
Disease Ontology: DOID:5648; Disease Ontology
MeSH: C562943; MeSH
NCI Thesaurus: C4715; NCI Thesaurus
Orphanet: ORPHA:251899; Orphanet
Highest stage of its drugs: Phase 3, for 8 of its 13 drugs, from ClinicalTrials.gov; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
THIOTEPA	CHEMBL671	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TOPOTECAN	CHEMBL84	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
VINBLASTINE	CHEMBL159	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00602667	Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma	Phase 2	293	2019-01-30	Brain and Central Nervous System Tumors	CYCLOPHOSPHAMIDE, METHOTREXATE, TOPOTECAN, VINBLASTINE	Its record names the disease	ClinicalTrials.gov
NCT00392886	Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors	Phase 3	120		Brain and Central Nervous System Tumors	CARBOPLATIN, CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, METHOTREXATE, TEMOZOLOMIDE, THIOTEPA, VINCRISTINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04400851	Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors	Phase 1	18		Pediatric Cancer	SINTILIMAB	Its record names the disease	ClinicalTrials.gov
NCT06357377	A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors	Phase 1	12		Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma	PERILLYL ALCOHOL	Its record names the disease	ClinicalTrials.gov
NCT04994977	Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery	Phase 1	1		Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma	CARBOPLATIN, MELPHALAN, TOPOTECAN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Intermediate-Risk Group vs High-Risk Group: Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan	1 of 1	20 of 27	28	NCT00602667	Trial comparisons
Intermediate-Risk Group vs High-Risk Group: Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan	0 of 1	8 of 27	28	NCT00602667	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37828033	DERIVED	1	PubMed
33945291	DERIVED	1	PubMed
33502920	DERIVED	1	PubMed
29778738	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016718

GET https://conductscience.org/api/diseases/v1/MONDO_0016718/drugs

API reference For AI assistants